These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 29717168)
61. FXR: a metabolic regulator and cell protector. Wang YD; Chen WD; Moore DD; Huang W Cell Res; 2008 Nov; 18(11):1087-95. PubMed ID: 18825165 [TBL] [Abstract][Full Text] [Related]
62. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Wu W; Zhu B; Peng X; Zhou M; Jia D; Gu J Biochem Biophys Res Commun; 2014 Jan; 443(1):68-73. PubMed ID: 24269813 [TBL] [Abstract][Full Text] [Related]
63. Farnesoid X receptor: from medicinal chemistry to clinical applications. Fiorucci S; Mencarelli A; Distrutti E; Zampella A Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613 [TBL] [Abstract][Full Text] [Related]
64. Ku proteins function as corepressors to regulate farnesoid X receptor-mediated gene expression. Ohno M; Kunimoto M; Nishizuka M; Osada S; Imagawa M Biochem Biophys Res Commun; 2009 Dec; 390(3):738-42. PubMed ID: 19833092 [TBL] [Abstract][Full Text] [Related]
65. Farnesoid X Receptor Activation Promotes Hepatic Amino Acid Catabolism and Ammonium Clearance in Mice. Massafra V; Milona A; Vos HR; Ramos RJJ; Gerrits J; Willemsen ECL; Ramos Pittol JM; Ijssennagger N; Houweling M; Prinsen HCMT; Verhoeven-Duif NM; Burgering BMT; van Mil SWC Gastroenterology; 2017 May; 152(6):1462-1476.e10. PubMed ID: 28130067 [TBL] [Abstract][Full Text] [Related]
66. FXR and NASH: an avenue for tissue-specific regulation. Henry Z; Meadows V; Guo GL Hepatol Commun; 2023 May; 7(5):. PubMed ID: 37058105 [TBL] [Abstract][Full Text] [Related]
68. Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties. Finamore C; Baronissi G; Marchianò S; Di Leva FS; Carino A; Monti MC; Limongelli V; Zampella A; Fiorucci S; Sepe V Molecules; 2019 Mar; 24(6):. PubMed ID: 30884797 [TBL] [Abstract][Full Text] [Related]
69. Intestine-specific FXR agonists as potential therapeutic agents for colorectal cancer. Yin Y; Wang M; Gu W; Chen L Biochem Pharmacol; 2021 Apr; 186():114430. PubMed ID: 33556338 [TBL] [Abstract][Full Text] [Related]
70. Structural insight into the molecular mechanism of cilofexor binding to the farnesoid X receptor. Jiang L; Liu X; Wei H; Dai S; Qu L; Chen X; Guo M; Chen Y Biochem Biophys Res Commun; 2022 Mar; 595():1-6. PubMed ID: 35091108 [TBL] [Abstract][Full Text] [Related]
71. Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation. Schuster D; Markt P; Grienke U; Mihaly-Bison J; Binder M; Noha SM; Rollinger JM; Stuppner H; Bochkov VN; Wolber G Bioorg Med Chem; 2011 Dec; 19(23):7168-80. PubMed ID: 22018919 [TBL] [Abstract][Full Text] [Related]
72. Identification and characterization of novel splice variants of human farnesoid X receptor. Mustonen EK; Lee SML; Nieß H; Schwab M; Pantsar T; Burk O Arch Biochem Biophys; 2021 Jul; 705():108893. PubMed ID: 33930378 [TBL] [Abstract][Full Text] [Related]
74. Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast. Schierle S; Helmstädter M; Schmidt J; Hartmann M; Horz M; Kaiser A; Weizel L; Heitel P; Proschak A; Hernandez-Olmos V; Proschak E; Merk D ChemMedChem; 2020 Jan; 15(1):50-67. PubMed ID: 31670489 [TBL] [Abstract][Full Text] [Related]
75. Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist. Hu L; Ren Q; Deng L; Zhou Z; Cai Z; Wang B; Li Z Eur J Med Chem; 2021 Feb; 211():113106. PubMed ID: 33360559 [TBL] [Abstract][Full Text] [Related]
76. Selective Photoaffinity Probe for Monitoring Farnesoid X Receptor Expression in Cultured Cells. Xu XW; Zhu Y; Song JZ; Zou GQ; Zhao Z; Zheng QL; Cao LJ; Wang GJ; Wang H; Hao HP Anal Chem; 2022 Aug; 94(30):10722-10729. PubMed ID: 35853240 [TBL] [Abstract][Full Text] [Related]
77. CEBPB regulates the bile acid receptor FXR to accelerate colon cancer progression by modulating aerobic glycolysis. Wang Z; Pang J; Wang L; Dong Q; Jin D J Clin Lab Anal; 2022 Nov; 36(11):e24703. PubMed ID: 36129029 [TBL] [Abstract][Full Text] [Related]
78. Optical control of the nuclear bile acid receptor FXR with a photohormone. Morstein J; Trads JB; Hinnah K; Willems S; Barber DM; Trauner M; Merk D; Trauner D Chem Sci; 2020 Jan; 11(2):429-434. PubMed ID: 32190263 [TBL] [Abstract][Full Text] [Related]
79. Characterization of a Structural Leoligin Analog as Farnesoid X Receptor Agonist and Modulator of Cholesterol Transport. Ladurner A; Linder T; Wang L; Hiebl V; Schuster D; Schnürch M; Mihovilovic MD; Atanasov AG; Dirsch VM Planta Med; 2020 Oct; 86(15):1097-1107. PubMed ID: 32485752 [TBL] [Abstract][Full Text] [Related]
80. A New FXR Ligand Chemotype with Agonist/Antagonist Switch. Helmstädter M; Vietor J; Sommer J; Schierle S; Willems S; Kaiser A; Schmidt J; Merk D ACS Med Chem Lett; 2021 Feb; 12(2):267-274. PubMed ID: 33603974 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]